HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Misawa, Y. Articles by Kato, M. Search for Related Content PubMed PubMed Citation Articles by Misawa, Y. Articles by Kato, M.

The Journal of Thoracic and Cardiovascular Surgery, Vol 105, 168-172, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Clinical experience with the Omnicarbon prosthetic heart valve

Y Misawa, T Hasegawa and M Kato
Department of Thoracic and Cardiovascular Surgery, Jichi Medical School, Tochigi, Japan.

The Omnicarbon prosthetic heart valve (Medical Inc., Inver Grove Heights, Minn.) was implanted in 124 patients (mean age 53 +/- 11 years); 66 of them had aortic valve replacement, 40 had mitral valve replacement, and 18 had both aortic and mitral valve replacement. Preoperatively 76.6% were in New York Heart Association class 3 or 4, and 84.7% were in class 1 or 2 after the operation. There were six (4.8%) early deaths and seven late deaths. Survival was 85% +/- 6% at 6 years in the aortic valve replacement group, 94% +/- 4% at 3 years in the mitral valve replacement group, and 78% +/- 11% at 4 years in the double valve replacement group. Freedom from cardiac death was 89% +/- 4% at 6 years (2.0% per patient-year) in the aortic valve replacement group, 94% +/- 4% at 3 years (1.8% per patient-year) in the mitral valve replacement group, and 78% +/- 11% at 4 years (5.7% per patient- year) in the double valve replacement group. There were six valve- related complications. Freedom from valve-related complications was 92% +/- 4% at 6 years (1.5% per patient-year) in the aortic valve replacement group, 97% +/- 3% at 3 years (1.8% per patient-year) in the mitral valve replacement group, and 83% +/- 11% at 4 years (5.7% per patient-year) in the double valve replacement group. Cerebral hemorrhage was seen in two patients in the aortic valve replacement group. Freedom from all events was 80% +/- 7% at 6 years in the aortic valve replacement group, 88% +/- 6% at 3 years in the mitral valve replacement group, and 78% +/- 11% at 4 years in the double valve replacement group. Elevation of the postoperative serum lactate dehydrogenase levels was minimal in all groups. The maximum opening angle at rest was 60.0 +/- 8.9 degrees in the aortic position and 54.1 +/- 6.6 degrees in the mitral position. In conclusion, the Omnicarbon prosthesis had excellent postoperative clinical status and negligible hemolysis.

This article has been cited by other articles:

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986. [Full Text]

				S. Torregrosa, J. Gomez-Plana, F. J. Valera, J. Caffarena, J. M. Maronas, F. Garcia-Sanchez, J. Peris, R. Frias, and J. M. Caffarena Long-term clinical experience with the omnicarbon prosthetic valve Ann. Thorac. Surg., September 1, 1999; 68(3): 881 - 886. [Abstract] [Full Text] [PDF]

				A. Kornberg, S. M. Wildhirt, C. Schulze, and E. Kreuzer Leaflet escape in Omnicarbon monoleaflet valve Eur. J. Cardiothorac. Surg., June 1, 1999; 15(6): 867 - 869. [Abstract] [Full Text] [PDF]

				T. Abe, K. Kamata, K. Kuwaki, K. Komatsu, and S. Komatsu Ten Years' Experience of Aortic Valve Replacement With the Omnicarbon Valve Prosthesis Ann. Thorac. Surg., April 1, 1996; 61(4): 1182 - 1187. [Abstract] [Full Text]